Role of renal and systemic vascular resistance for progression of chronic kidney disease - RenVas

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2010-023979-25-DK

Enrollment

110

Registered

2010-12-15

Start date

2011-01-03

Completion date

Unknown

Last updated

2015-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

We want to investigate whether increased vasodilitation ( angiotensin converting enzyme inhibitor and calcium channel blocker) compared to standard treatment ( beta-blocker and angiotensin converting enzyme inhibitor) reduces the rate of decline of GFR in patients with chronic kidney disease (grade 3 to 4) and hypertension. Patients with ischemic heart disease or congestive heart failure will be treated with Carvedilol if randomized to increased Vasodilitation. MedDRA version: 13.1 Level: LLT

Interventions

Trade Name: Ramipril Pharmaceutical Form: Tablet CAS Number: 87333-19-5 Other descriptive name: RAMIPRIL Trade Name: Losartan Pharmaceutical Form: Tablet INN or Proposed INN: LOSARTAN CAS Number: 114

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: CKD grade 3-4 Hypertension (Blood pressure > 130/80 measured 24 h ambulatory) Age> 18 years Fertile women: Must have safe contraception Informed consent. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Claustrophobia in a degree which makes MRI impossible Ultrasound verified polycystic kidney disease Pregnancy or wish to be pregnant Contraindications to MRI (Pacemaker, metal implants incompatible with MRI) Allergy to the medicine used in the trail Blood pressure blow 130/80 (24 h ambulatory) without antihypertensive drugs Blood pressure over 130/80 (24h ambulatory) while treatmented with maximum dose of beta-blocker, ACEi and CCB simultaneously.

Design outcomes

Primary

Measure	Time frame
Main Objective: Does increased vasodilation reduce loss of kidney function in patients with CKD grad 3-4 and hypertension.;Secondary Objective: Will increased vasodilation normalize the structure of resistance vessels in patients with CKD grade 3-4 and hypertension. ;Primary end point(s): Difference in decline of GFR (glomerular filtation rate) in the two treatment arms.	—

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026